CSL Limited (CMXHF)
OTCMKTS · Delayed Price · Currency is USD
150.82
+2.80 (1.89%)
Aug 21, 2025, 1:09 PM EDT
CSL Limited Revenue
In the fiscal year ending June 30, 2025, CSL Limited had annual revenue of $15.56B with 5.12% growth. CSL Limited had revenue of $7.08B in the half year ending June 30, 2025, with 15.49% growth.
Revenue
15.56B
Revenue Growth
+5.12%
P/S Ratio
4.53
Revenue / Employee
520.26K
Employees
32,698
Market Cap
70.42B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2025 | 15.56B | 758.00M | 5.12% |
Jun 30, 2024 | 14.80B | 1.49B | 11.19% |
Jun 30, 2023 | 13.31B | 2.75B | 26.02% |
Jun 30, 2022 | 10.56B | 252.00M | 2.44% |
Jun 30, 2021 | 10.31B | 1.16B | 12.67% |
Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 105.45M |
Glass House Brands | 221.55M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.09M |
Silence Therapeutics | 27.17M |
Global Cord Blood | 196.10M |
CSL Limited News
- 2 days ago - CSL Limited falls as layoffs overshadow FY25 results - Seeking Alpha
- 2 days ago - CSL Limited (CSLLY) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Full Year 2025 CSL Ltd Earnings Presentation Transcript - GuruFocus
- 2 days ago - CSL Limited 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 2 days ago - Australian biopharma firm CSL posts 14% rise in annual profit - Reuters
- 2 months ago - U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start - PRNewsWire
- 3 months ago - England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy - PRNewsWire
- 4 months ago - CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy - PRNewsWire